$HIMS · Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach

episode briefing

extracted intelligence

Antonio Linares

Superpower CEO Max Marchione on AI Doctors, Peptides & Gene Editing

now viewing▶ 10:20

Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach

2026-01-12 · 6 company · 6 thematic

sentiment

2 bull0 bear4 neu

speakers

max marchione

Australian-born founder who solved his own decade-long misdiagnosis at 18 via '10X doctor.' Founded Superpower 3 years ago to democratize frontier medicine via AI-first health platform. Raised $40M Series A, growing thousands of members/month. Building digital twin, AI clinical reasoning, and full-stack action layer.

quote

“If I look at HIMS, the path is basically the e-commerce or the CPG path. Pick a skew for which you can acquire users very effectively and cheaply via paid ads. In time, add a little bit more brand largely for awareness and to decrease CAC.…”

—max marchione

now playing · $HIMS

$SUPERPOWERbullish· high· posmax marchione

Superpower raises $40M Series A, growing thousands of members/month with AI-first health platform

Superpower builds AI-first health platform with 100+ biomarker testing ($199), digital twin, AI clinical reasoning (ensemble models + proprietary clinical canon), and action layer…

$HIMS···neutral· highmax marchione

Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach

Hims follows a CPG/e-commerce path (fastest to revenue/gross profit) but lacks lifestyle brand and tech layer; Superpower takes product-first tech approach with stronger retention…

$NVO···neutral· highmax marchione

Novo Nordisk and Eli Lilly will own future patented GLP-1 classes, making compounding risky long-term

Future GLP-1 generations will be patented by Eli Lilly and Novo Nordisk with defensible IP, making current compounding bets risky long-term despite short-term viability. The next…

$STEALTH-BIOSCIENCESneutral· lowmax marchione

Stealth Biosciences owns SS31 mitochondrial peptide, enforcing IP against unauthorized sellers

Stealth Biosciences holds IP on SS31 (mitochondrial peptide for longevity/energy) and actively sends cease-and-desist letters to unauthorized sellers, indicating defensible patent…

$OPENAIneutral· highmax marchione

ChatGPT Health is a 'nothing burger' but ChatGPT remains formidable as potential health demand aggregator

ChatGPT Health launch adds nothing new (just a tab) since ChatGPT already captures health queries, wants user context, and moves into action layer. However, ChatGPT could become t…

$LLY···bullish· mediummax marchione

Eli Lilly potentially undervalued but needs Pharma 2.0 transformation to own patient relationship

Eli Lilly could be underpriced despite trillion-dollar valuation, but must transition from Pharma 1.0 (disease drugs via payers/health systems) to Pharma 2.0 (wellness drugs direc…